DeciBio
Melissa Kolenovic has extensive experience in the biotech sector, currently serving as an Associate at DeciBio since January 2022, after holding the position of Senior Analyst. Prior to this role, Melissa worked at BioLegend, where duties included Global Sales Operations Associate from June 2021 to September 2021 and Quality Control Associate roles from September 2017 to May 2020. Melissa holds a Master's degree in Global Business Development from San Diego State University, obtained in August 2022, and a Bachelor's degree in Molecular and Cell Biology, with a focus on Immunology and Pathogenesis, from the University of California, Berkeley, earned in 2017.
DeciBio
1 followers
DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide the strategic insights that accelerate the development, adoption, and accessibility of personalized medicine. Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products. DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), immuno-oncology (the I/O BioMAP), omics market segmentation (the MarketBooks), and the entire life sciences industry (BioTrack). Internal teams such as the Culture Committee, Women* in Consulting, and Gays in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine.